Drugs / Hem101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06705530 | Nov 2024 → Oct 2025 | B-cell non-Hodgkin lymphoma, acute lymphoblastic leukemia | National Research Center for Hematology, Russia | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hem101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06705530 ↗ |
| Action | Deplete | “engineered to recognize and destroy cancer cells with the CD19 antigen” NCT06705530 ↗ |
| Modality | Cell therapy | “anti-CD19 CAR-T cell therapy” NCT06705530 ↗ |
| Route | Intravenous | “administered as an intravenous infusion” NCT06705530 ↗ |